GlassScriptPhysician profile
Fiore J Copare
NPI 1205869989
$4,134.85
in general payments reported to CMS, 2019-2025
28 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,681 · 2020: $946 · 2021: $790 · 2022: $79.10 · 2023: $26.21 · 2024: $362 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $624.46 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $472.47 | 2019-2025 | Airsupra |
| Glaxosmithkline, LLC. | $358.27 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $302.15 | 2019-2024 | Repatha, Otezla, Evenity |
| Pfizer INC. | $234.11 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $221.51 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $220.23 | 2019-2025 | Zoryve, Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.47 | 2020-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $195.14 | 2019-2021 | |
| Amarin Pharma, INC. | $192.92 | 2019-2021 | |
| Astellas Pharma US INC | $144.13 | 2019 | |
| Lilly USA, LLC | $140.57 | 2019-2025 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.03 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $118.59 | 2019-2021 | |
| Philips North America LLC | $94.48 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $82.96 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.32 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $70.54 | 2019-2020 | |
| Abbvie INC. | $56.90 | 2019-2021 | |
| Allergan, INC. | $46.62 | 2019-2020 | |
| Dexcom, INC. | $33.99 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.46 | 2022 | |
| Abbott Laboratories | $21.27 | 2024 | Freestyle Libre 3 |
| Lundbeck LLC | $17.07 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $15.28 | 2025 | Rexulti |
| Alexion Pharmaceuticals, INC. | $14.34 | 2020 | |
| Nestle Healthcare Nutrition INC. | $14.12 | 2020 | |
| Circassia INC. | $13.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fiore Copare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.